{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:16:32Z","timestamp":1760012192070,"version":"build-2065373602"},"reference-count":16,"publisher":"Scientific Scholar","content-domain":{"domain":["nmji.in"],"crossmark-restriction":true},"short-container-title":["NMJI"],"abstract":"\nBackground<\/jats:title>\nThere is a paucity of newer studies focusing on survival patterns in the era of targeted pulmonary vasodilators in Eisenmenger syndrome (ES). We aimed to study the survival pattern, mortality predictors and outcome of targeted pulmonary vasodilator therapy in patients with ES.<\/jats:p>\n<\/jats:sec>\n\nMethods<\/jats:title>\nThis was a single-centre retrospective observational study of patients treated between January 2000 and January 2020. Consecutive patients with clinical and echo- cardiographic and\/or cardiac catheterization diagnoses of ES were included in the study. Shunt types were classified into pre-tricuspid shunts, post-tricuspid shunts and complex lesions. Clinical outcomes and treatment data of all patients were assessed.<\/jats:p>\n<\/jats:sec>\n\nResults<\/jats:title>\nOf 206 patients, 139 were female with a mean (SD) age of 23.4 (14.3) years. Pre-tricuspid shunts were the most common shunt type, with atrial septal defect being the most common anatomical defect. During a mean (SD) follow-up of 7.1 (6.2) years, a significant decline in mean resting systemic saturation and WHO functional class on follow-up was observed. Atrial arrhythmias and right ventricular dysfunction were the most common in pretricuspid shunt lesions. ES secondary to complex defects had the worst prognosis with early attrition. Survival patterns were equally poor in complex defects and pre-tricuspid defects after the onset of Eisenmenger physiology. Targeted pulmonary vasodilator therapy was associated with better survival, irrespective of monotherapy or dual therapy. Congestive heart failure was the most common cause of death. Survival at 5 and 10 years in the disease modifier treatment group was 84% and 69% while in the treatment na\u00efve group was 66% and 44%. Resting systemic saturation <80% on follow-up, the presence of atrial arrhythmias and the absence of disease-targeted therapy were independently associated with mortality.<\/jats:p>\n<\/jats:sec>\n\nConclusion<\/jats:title>\nThe long-term survival of patients with ES remains poor in the era of targeted pulmonary vasodilator therapy. ES resulting from complex cyanotic congenital heart diseases has the worst survival outcomes. Although pretricuspid shunt ES patients survived longer, they tended to decompensate at lower mean pulmonary artery pressure than all other subgroups with ES. Targeted pulmonary vasodilator therapy may be associated with improved functional class and survival benefits in ES.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/nmji_203_2023","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T11:36:48Z","timestamp":1760009808000},"page":"197-202","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term outcomes of Eisenmenger syndrome in the era of targeted pulmonary vasodilator therapy"],"prefix":"10.25259","volume":"38","author":[{"given":"VISHNU","family":"SUGATHAN","sequence":"first","affiliation":[{"name":"Department of Cardiology, Sree Chitra Tirunal Institute of Medical Sciences and Technology, Medical College P.O., Thiruvananthapuram, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HARIKRISHNAN","family":"SIVADASANPILLAI","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sree Chitra Tirunal Institute of Medical Sciences and Technology, Medical College P.O., Thiruvananthapuram, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SANJAY","family":"GANAPATHI","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sree Chitra Tirunal Institute of Medical Sciences and Technology, Medical College P.O., Thiruvananthapuram, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ARUN","family":"GOPALAKRISHNAN","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sree Chitra Tirunal Institute of Medical Sciences and Technology, Medical College P.O., Thiruvananthapuram, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AJITKUMAR","family":"VALAPARAMBIL","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sree Chitra Tirunal Institute of Medical Sciences and Technology, Medical College P.O., Thiruvananthapuram, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KAVASSERY MAHADEVAN","family":"KRISHNAMOORTHY","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sree Chitra Tirunal Institute of Medical Sciences and Technology, Medical College P.O., Thiruvananthapuram, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ANTONY","family":"STANLEY","sequence":"additional","affiliation":[{"name":"Achutha Menon Centre for Health Science Studies, Sree Chitra Tirunal Institute of Medical Sciences and Technology, Thiruvananthapuram, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"10.25259\/NMJI_203_2023\/ref-1","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1136\/bmj.2.5099.755","article-title":"The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt","volume":"2","author":"Wood","year":"1958","journal-title":"Br Med J"},{"key":"10.25259\/NMJI_203_2023\/ref-2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0167-5273(94)90166-X","article-title":"The prognosis for patients with Eisenmenger syndrome of various aetiology","volume":"45","author":"Saha","year":"1994","journal-title":"Int J Cardiol"},{"key":"10.25259\/NMJI_203_2023\/ref-3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, doubleblind, randomized, placebo-controlled study","volume":"114","author":"Gali\u00e8","year":"2006","journal-title":"Circulation"},{"key":"10.25259\/NMJI_203_2023\/ref-4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1747-0803.2011.00561.x","article-title":"Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover","volume":"6","author":"Mukhopadhyay","year":"2011","journal-title":"Congenit Heart Dis"},{"key":"10.25259\/NMJI_203_2023\/ref-5","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":"Updated clinical classification of pulmonary hypertension","volume":"54","author":"Simonneau","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.25259\/NMJI_203_2023\/ref-6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1161\/CIR.0000000000000602","article-title":"2018 AHA\/ACC guideline for the management of adults with congenital heart disease: Executive summary: A report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"139","author":"Stout","year":"2019","journal-title":"Circulation"},{"key":"10.25259\/NMJI_203_2023\/ref-7","first-page":"100","article-title":"Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome","volume":"15","author":"Hopkins","year":"1996","journal-title":"J Heart Lung Transplant"},{"key":"10.25259\/NMJI_203_2023\/ref-8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1161\/CIRCULATIONAHA.109.883876","article-title":"Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension","volume":"121","author":"Dimopoulos","year":"2010","journal-title":"Circulation"},{"key":"10.25259\/NMJI_203_2023\/ref-9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.acvd.2017.01.006","article-title":"The outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study","volume":"110","author":"Hascoet","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"key":"10.25259\/NMJI_203_2023\/ref-10","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/eurheartj\/ehv743","article-title":"Current therapy and outcome of Eisenmenger syndrome: Data of the German National Register for congenital heart defects","volume":"37","author":"Diller","year":"2016","journal-title":"Eur Heart J"},{"key":"10.25259\/NMJI_203_2023\/ref-11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ijcard.2010.10.051","article-title":"Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology","volume":"155","author":"D'Alto","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.25259\/NMJI_203_2023\/ref-12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1097\/MBC.0000000000000523","article-title":"Platelet abnormalities in adults with severe pulmonary arterial hypertension related to congenital heart defects (Eisenmenger syndrome)","volume":"27","author":"Remkov\u00e2","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.25259\/NMJI_203_2023\/ref-13","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1161\/CIRCULATIONAHA.104.509869","article-title":"Pulmonary neovascularity: A distinctive radiographic finding in Eisenmenger syndrome","volume":"112","author":"Sheehan","year":"2005","journal-title":"Circulation"},{"key":"10.25259\/NMJI_203_2023\/ref-14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0002-9149(03)00535-6","article-title":"Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension","volume":"92","author":"Perloff","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.25259\/NMJI_203_2023\/ref-15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00019501-200502000-00004","article-title":"The remarkable right ventricle of patients with Eisenmenger syndrome","volume":"16","author":"Hopkins","year":"2005","journal-title":"Coron Artery Dis"},{"key":"10.25259\/NMJI_203_2023\/ref-16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ijcard.2014.11.100","article-title":"Physiological differences between various types of Eisenmenger syndrome and relation to outcome","volume":"179","author":"Moceri","year":"2015","journal-title":"Int J Cardiol"}],"container-title":["The National Medical Journal of India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/nmji.in\/long-term-outcomes-of-eisenmenger-syndrome-in-the-era-of-targeted-pulmonary-vasodilator-therapy\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nmji.in\/long-term-outcomes-of-eisenmenger-syndrome-in-the-era-of-targeted-pulmonary-vasodilator-therapy\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T11:36:48Z","timestamp":1760009808000},"score":1,"resource":{"primary":{"URL":"https:\/\/nmji.in\/long-term-outcomes-of-eisenmenger-syndrome-in-the-era-of-targeted-pulmonary-vasodilator-therapy\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":16,"alternative-id":["10.25259\/NMJI_203_2023"],"URL":"https:\/\/doi.org\/10.25259\/nmji_203_2023","relation":{},"ISSN":["2583-150X","0970-258X"],"issn-type":[{"value":"2583-150X","type":"electronic"},{"value":"0970-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"article-number":"197"}}